INIS
kidneys
100%
patients
69%
transplants
63%
diseases
60%
covid-19
49%
antibodies
39%
dialysis
32%
coronaviruses
31%
vaccines
22%
levels
21%
control
20%
comparative evaluations
14%
therapy
12%
messenger-rna
11%
safety
11%
units
10%
interleukins
10%
risks
10%
netherlands
9%
antibody formation
8%
receptors
7%
tools
7%
hybrids
7%
immunity
7%
filtration
7%
equations
7%
creatinine
7%
adults
7%
blood
7%
doses
7%
Keyphrases
Kidney Transplant Recipients
60%
COVID-19
40%
Vaccination
32%
SARS-CoV-2 Vaccination
24%
Antibody Level
22%
COVID-19 Vaccination
21%
Chronic Kidney Disease
20%
Dialysis Patients
19%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
15%
Patients with Kidney Disease
15%
Dialysis
13%
B Cell Response
12%
Immune Response
12%
COVID-19 Pandemic
11%
Mycophenolic Acid
11%
Kidney Replacement Therapy
11%
Netherlands
10%
Antibody Response
10%
Interleukin-21 (IL-21)
10%
IgG Antibody
10%
Chronic Kidney Disease Stage
10%
Antibody Formation
8%
Immunosuppressive Therapy
8%
Long-term Safety
8%
Long-term Efficacy
8%
Kidney Disease
8%
Prospective Observational Study
7%
Receptor-binding Domain
7%
COVID-19 Severity
7%
Nested Case-control Study
7%
Medicine and Dentistry
Kidney Graft
46%
COVID-19
42%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
COVID-19 Vaccination
28%
Chronic Kidney Disease
28%
Nephropathy
24%
Immune Response
16%
B Cell
15%
Messenger RNA
13%
Renal Replacement Therapy
11%
Antibody Response
10%
Interleukin 21
10%
Mycophenolate Mofetil
9%
Memory T Cell
9%
Kidney Function
8%
Kidney Transplantation
7%
Health Status
7%
Hemodialysis
7%
Post-COVID-19
7%
Cohort Study
7%
Immunosuppressive Treatment
7%
Awareness
7%
Mental Health
7%
Frailty
7%
Triage
7%
Peritoneal Dialysis
7%
Intensive Care Unit
7%
Symptomatic Treatment
7%
Hybrid Immunity
7%
Case-Control Study
7%